Lifeshield Medical Invites You to the 7th VB100 Future Healthcare Top 100 Summit 2023
Over the past decade, the global healthcare industry has undergone significant restructuring, a transformation accelerated by the COVID-19 pandemic since 2020. Having withstood the compounded challenges of global upheavals and the century-defining pandemic from 2020 to 2022, 2023 marked the first year for implementing the strategic arrangements outlined at the 20th National Congress of the Communist Party of China, as well as a critical year for advancing the 14th Five-Year Plan. Only by accumulating strength, demonstrating the resilience to “stand firm amidst countless trials,” and embodying the spirit to “forge ahead despite growing difficulties,” can innovators in the healthcare sector bolster their confidence through decisive action and successfully deliver on the era’s mandate for high-quality development in healthcare.
The 7th Future Healthcare 100 Conference, themed "No Questions Asked About West or East," was organized byVCBeat VB100, Eggshell Research InstituteHosted by,Shanghai Zhangjiang GroupStrategic Collaboration, integrating “cutting-edge academic research expertise, comprehensive industry insights, and keen awareness of capital trends,” was held at the Zhangjiang Science Hall in Shanghai from May 5–7, 2023, joining forces with peers to explore the innovative future of the greater health industry and embark on a new journey in medical innovation.
After six successful editions, the conference has become China’s largest and most information-rich ecosystem summit for the integration of industry and capital in the medical and health innovation sector. Centered on “connecting global wisdom, sharing cutting-edge technologies, inspiring the technological future, and focusing on venture capital interaction,” it sets the trend for innovation and investment in China’s medical and health field. The 7th Future Healthcare 100 Conference in 2023 will feature three major summits, more than 20 thematic forums covering specialized sectors, release the Future Healthcare 100 series rankings and awards, publish over ten series reports, and host seven concurrent networking events. Distinguished guests and attendees from government agencies, academicians and scientists, clinical and research experts, Fortune 500 and listed companies, top-tier investment institutions and securities firms, and innovative healthcare enterprises will be invited to participate. This gathering of minds aims to provide insights to the industry and usher in a new future.
“Only Ask for Courage, Only Ask for Blooming, No Questions of West or East” Makes a Powerful Arrival!
Over time, patients with cardiovascular diseases such as hypertension and coronary heart disease are progressing to the final frontier of cardiovascular care: heart failure. The next decade represents a golden era for the development of heart failure medical devices, and the heart failure device market is poised to become the next billion-dollar opportunity driven by cardiovascular disease.
The Future Healthcare Top 100 Conference also featuredFrontier Innovation Forum on Vascular Intervention,Clinical experts, industry-leading companies, and investment institutions will be invited to provide a comprehensive discussion from their respective perspectives on technological innovations, current research and clinical practices, product landscapes, and development trends in vascular interventional therapy.
This Conference,Tim A.S. Kaufmann, Founder & CEO of enmodes GmbH, GermanyProfessorInvited to attend and deliver a keynote address, sharing insights on the application and latest advancements of flow field design in blood pumps and pVADs.Mr. Chen Zulin, CEO of Life Shield Medicalwill also attend and participate in the roundtable session, engaging with representatives from across the industry to explore opportunities and challenges in sector development, spark intellectual exchange, and foster dialogue on ecosystem building.
Conference Time:
May 5–7, 2023
Time of the Frontier Innovation Forum on Vascular Intervention:
May 6, 2023
Conference Venue:
Shanghai Zhangjiang Science Hall (No. 1393 Haike Road, Pudong New Area, Shanghai)
Conference Registration:
(General Conference Pass: Enjoy Access to 30+ Forums)
LifeShield Medical Group is a Sino-German multinational medical device company specializing in the research and development, manufacturing, and sales of innovative technologies in the field of life support. The group owns two wholly-owned subsidiaries: LifeShield Medical Technology (Suzhou) Co., Ltd. and enmodes GmbH (Germany).
LifeShield Medical Technology (Suzhou) Co., Ltd. is positioned as the Asia-Pacific and China headquarters of LifeShield Medical Group, responsible for local innovative R&D in China, global production bases, and Asia-Pacific market expansion;
Germany-based enmodes serves as the European headquarters of Life Shield Medical Group, overseeing the global R&D center and EU market expansion;
LifeShield Medical Technology (Suzhou) Co., Ltd., formerly known as Suzhou LungShield Medical Technology Co., Ltd.,Founded in 2018, the company has focused from its inception on unmet clinical needs in the cardiovascular field. It is dedicated to the research, development, and manufacturing of innovative medical devices in the internationally advanced field of extracorporeal life support technology. The company is committed to providing high-quality products and treatment solutions for patients with cardiovascular diseases and respiratory failure, helping to alleviate their suffering and improve their quality of life.
The company’s core management team comprises senior executives from multinational corporations with extensive experience in the cardiovascular field, all of whom possess substantial expertise in the research and development, manufacturing, and commercialization of cardiovascular medical devices.
China’s R&D team boasts extensive experience in medical device development, with members hailing from top-tier universities and renowned medical companies both domestically and internationally. Leveraging its professional scientific research and engineering teams, along with years of deep industry expertise and technological accumulation, the company has secured multiple patents both in China and abroad. Key R&D personnel have been recognized as Leading Talents for Innovation and Entrepreneurship in Suzhou High-Tech Zone and under the Gusu Leading Talents Program for Innovation and Entrepreneurship.
As the global manufacturing base for LifeShield Medical, we currently operate two ISO Class 10,000 cleanroom production facilities in Suzhou, complemented by comprehensive procurement, production, and quality management systems. Products manufactured in Suzhou will be distributed from here to serve patients worldwide.
enmodes GmbHHeadquartered in Aachen, Germany, and founded in 2011, the company boasts a team of more than 20 top-tier scientists and engineers from around the world. It was ranked No. 1 among European medical device startups by the EIT (European Institute for Innovation and Technology). Over the past decade, the company has provided R&D and design services to numerous renowned multinational medical device corporations, supporting some clients in conducting clinical trials and scaling up to mass production. Its product portfolio includes interventional left ventricular assist systems, extracorporeal blood pumps, and extracorporeal artificial oxygenation systems. Multiple products have successfully completed human clinical trials and received approval for market entry in Europe and the United States, with some becoming globally leading solutions.
CompanyR&D Pipeline：
LifeShield Medical is currently focused on a "full-platform" layout in the field of life support, based on core blood pump technology, ranging from extracorporeal support to endovascular interventional therapy. The main product pipelines are:
1. New GenerationInterventional Artificial HeartSystem (pVAD)：
2. ECMO Extracorporeal Membrane Oxygenation System
3. Next-Generation Carbon Dioxide Removal System (ECCO2R)
As a Sino-German multinational medical technology company, LifeShield Medical will actively collaborate with domestic clinicians to continue the research, development, and commercialization of innovative life support system products and solutions for the heart, brain, lungs, liver, and kidneys, thereby meeting clinical demands in the Chinese and EU markets and serving more patients.